Understanding and incentivizing biosimilars

Hastings Law Journal

Volumn 64, Issue 1, 2012, Pages 57-81

  Kanter, Jason ^a   Feldman, Robin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873940514     PISSN: 00178322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (5)

1. Brady Huggett et al.. Public Biotech 2010-The Numbers, 29 NATURE BIOTECH. 585, 589 (2011)
2. A.J.F. Griffrrhs Et Al.. Modern Genetic Analysis (1999), Image Available At http://www.ncbi.nhn.nih.gov/boolcs/NBK21385 (hemoglobin protein structure
3. Gary Walsh & Roy Jefferis, Post-Translational Modifications in the Context of Therapeutic Proteins, 24 NATURE BIOTECH. 1241,1241-52 (2006).
4. RACHEL E . SHERMAN, BIOSIMILAR BIOLOGICAL PRODUCTS: BIOSIMILAR GUIDANCE WEBINAR (2012).
5. Marsha N. Cohen & Sami Sedghani, Pharmacy Law For California Pharmacists, 188-89